Home » News and events » LifeArc and Cleveland Clinic join forces to develop new monoclonal antibody therapeutics for patients with high unmet medical needs

LifeArc and Cleveland Clinic join forces to develop new monoclonal antibody therapeutics for patients with high unmet medical needs

News releases
3D illustration of antibody

LifeArc and Cleveland Clinic, a nonprofit, multispecialty academic medical centre, have signed a new 10-year Master Services Agreement (MSA) for the development of novel monoclonal antibody-based therapeutics for patients with unmet medical needs.

LifeArc will provide its expertise in humanisation of monoclonal antibodies (mAbs) to target key drivers of conditions identified by Cleveland Clinic including cancer and complement-mediated diseases. This MSA builds on a successful track record of the two organisations working together since 2019 on four humanisation projects, with a fifth project for 2025 already underway.

Professor Feng Lin, Lerner Research Institute, Cleveland Clinic said: “Working with LifeArc is a collaboration. Both sides of the team come together and bring their respective expertise to take the project forward.”

Dr. Jason Slingsby, Chief Business Officer at LifeArc said: “This collaboration with Cleveland Clinic is a groundbreaking moment for research into the development of monoclonal antibodies. Combining our expertise could lead to the development of new clinical candidate mAbs and give hope to patients who need it the most. Monoclonal antibodies are offering us new ways to target a wide range of conditions and I’m excited to see what our collaboration will develop over the next 10 years.

The agreement brings together two leading innovators in monoclonal antibody development to deliver new treatments for patients with unmet medical needs. Cleveland Clinic, based in Cleveland, Ohio, with locations around the world, is renowned for delivering high-quality research and cutting-edge treatments to patients. LifeArc brings over 30 years of expertise in antibody humanisation and engineering, which has seen five licensed medicines on the market including Keytruda® (pembrolizumab), one of the best-selling cancer treatments in 2024, and Leqembi®(lecanemab), a new treatment for early-stage Alzheimer’s disease.


Media contact

Hannah Severyn

Head of Media and PR at LifeArc